Discover how non-REM sleep breakthroughs from UC Berkeley and new p-tau217 genetic combo tests published in September 2026 are transforming Alzheimer's forecasting and prevention.

 Discover how groundbreaking research at Karolinska Institutet on Estrogen Receptor Beta (ERβ) and stem-cell-derived "mini-brains" is opening doors to personalized, sex-specific Alzheimer's treatments without systemic side effects.

The FDA cleared the PrecivityAD2 blood test for adults 40+ showing cognitive symptoms. Learn how this 97.6% accurate test replaces painful spinal taps.

Think reaching age 90 means you've escaped dementia? A major new UC Davis study reveals that risk continues to rise—and impacts certain groups much more.

A breakthrough Harvard study shows how a simple digital map applied to standard MRI scans can predict when early-onset Alzheimer's patients will transition to dementia.

Learn how two breakthrough blood tests—ultrasonic PMCA and the p-tau217 biomarker—are set to revolutionize Alzheimer's detection, predicting cognitive decline up to 10 years before symptoms appear.

Groundbreaking 2026 research reveals structural brain changes precede amyloid plaques by 7+ years, transforming early detection, atypical Alzheimer's care, and targeted treatments.

Discover how 2026 Alzheimer’s research is shifting from amyloid plaques to multi-target precision medicine, neuroinflammation, and complex network biology.

Discover how ETH Zurich researchers uncovered GRK2 enzyme aggregates as a novel Alzheimer's target, offering new hope for energy-restoring therapies.

Your brain consumes roughly 20% of your body's energy, meaning it relies on a massive network of blood vessels. To protect your central nervous system from harmful chemical swings and infections, the cells lining these blood vessels fit together like microscopic puzzle pieces sealed with airtight biological glue. This tight network is the Blood–Brain Barrier.

A recent breakthrough study from Duke Health, published on August 10, 2026, provides much-needed clarity on how lecanemab performs when administered outside the strict confines of a trial. For families and patients navigating this new landscape, the findings offer both reassurance and a roadmap for safety.

The recent study focuses on the hippocampus—the brain's primary center for memory and learning. Think of the hippocampus as a lush garden. For the first five decades of your life, this garden is tended by "resident immune cells.

There is a massive blind spot in the current landscape of neurodegenerative care, and it’s one that should keep every health-tech developer awake at night. For decades, the public and medical consciousness has viewed Alzheimer’s disease through a single, narrow lens: the loss of memory. We imagine the grandmother who forgets a name or the father who loses his keys.

At Glassbury AI, we believe health justice starts with inclusion. We are using modern technology to fix this recruitment crisis by building trust and making the process easy to understand for every family.

For years, we have known that people with early-stage Alzheimer’s often struggle to get a good night's rest. For a long time, scientists thought this was simply because of "plaques"—sticky protein buildups called amyloid—clogging up the brain. However, new research from the University of Kentucky suggests the problem isn't just the plaques

For decades, the path to an Alzheimer’s diagnosis has been a marathon, not a sprint. Patients and families often face months of uncertainty, navigating a complex web of specialist referrals, expensive PET scans, and invasive spinal taps.

In the high-stakes world of clinical research, fixed machine learning models face a silent, inevitable threat: drift. As clinical practices shift, lab equipment is recalibrated, and patient populations evolve, static algorithms slowly degrade in accuracy.

If a patient's kidneys aren't clearing waste efficiently, p-tau217 levels in the blood naturally back up and spike—creating a terrifying "false positive" for Alzheimer’s pathology in patients who are cognitively healthy.

At Glassbury AI, we believe true precision medicine requires algorithms that understand basic biology—including the plumbing.

Focus: Aligning Glassbury AI’s engineering approach with the massive global computational shift and a newly discovered cellular death mechanism.

Focus: Demystifying how Glassbury AI structures data, paired with the industry's shift from symptom-based diagnosis to multi-omic reality.